No Picture
News

Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the study design for SAPPHIRE, a Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin. This pivotal… Click here to view original post… […]

No Picture
News

nference Study Produces First Molecular Hypothesis Explaining COVID-19-Induced Myocarditis

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Nov. 30, 2021 /PRNewswire/ — nference, the AI-driven health technology company, today announced publication of a preprint study in bioRxiv that found the genetic alteration of some linear peptides expressed specifically in the human heart are mimicked by the SARS-CoV-2 polyprotein (replicase). The study has been… Click here to view original post… […]

No Picture
News

Study Finds Orgasmic Meditation Triggers Substantial “Mystical Experience,” Which Has Been Linked to Treatment of Depression

CAMBRIDGE, Mass.–(BUSINESS WIRE)–A new study published by researchers from the Institute of OM Foundation in California found that Orgasmic Meditation (“OM”) can trigger a substantial mystical experience in both partners. The study, published in the journal F1000 Research, found that the effect of Orgasmic Meditation is equivalent to a moderate… Click here to view original post… […]

No Picture
News

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma

BARCELONA, Spain: BARCELONA, Spain, Nov. 30, 2021 /PRNewswire/ — Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies, today announced the opening of its 300th plasma donor center in the U.S., the company’s first-ever donation center in the state of Massachusetts and second… Click here to view original post… […]

No Picture
News

Particles for Humanity Announces Codex Approval of BMC as a Food Additive for Bouillon Fortification

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Nov. 30, 2021 /PRNewswire/ — Codex Alimentarius Commission has approved the addition of Basic Methacrylate Copolymer (BMC, INS 1205) to the General Standards for Food Additives (GSFA). Many countries rely on the standards set by Codex, so this approval should enable BMC’s use as a food… Click here to view original post… […]

No Picture
News

Iterative Scopes CE Marks SKOUT, its Innovative AI-Based Medical Device for Potential Colorectal Polyps Detection

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes CE Marks AI-based SKOUT, marking the product’s first regulatory certification and enabling its distribution and marketing in Europe Click here to view original post… […]

No Picture
News

Blue Earth Diagnostics Highlights Axumin® (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced a presentation on Axumin® (fluciclovine F 18) at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in Orlando, Fla., from… Click here to view original post… […]

No Picture
News

Biostage Hires David Green as Chief Executive Officer

HOLLISTON, Mass.: HOLLISTON, Mass., Nov. 30, 2021 /PRNewswire/ — Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced it has hired David Green… Click here to view original post… […]